Interactions of HIV-1 with antigen-presenting cells

Immunology and Cell Biology

Volumn 77, Issue 4, 1999, Pages 289-303

  Hewson, Tim ^a   Lone, Nazir ^a   Moore, Marilyn ^b   Howie, Sarah ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PPL Therapeutics   (United Kingdom)

Author keywords

Acquired immunodeficiency syndrome; Antigen presenting cells; Dendritic cells; Human immunodeficiency virus; Immune system; Macrophages

Indexed keywords

CYTOKINE;

ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNE SYSTEM; LONG TERMINAL REPEAT; PATHOGENESIS; PROMOTER REGION; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032801008     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00833.x     Document Type: Review

References (182)

1. 1 Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral-blood T-cells. J. Immunol. 1993; 150: 4338-45.
2. 2 Boehme SA, Zheng LX, Lenardo MJ. Analysis of the CD4 co-receptor and activation-induced costimulatory molecules in antigen-mediated mature T-lymphocyte death. J. Immunol. 1995; 155: 1703-12.
3. 3 Arimilli S, Mumm JB, Nag B. Antigen-specific apoptosis in immortalized T cells by soluble MHC class 11-peptide complexes. Immunol. Cell Biol. 1996; 74: 96-104.
4. 4 Tucek-Szabo CL, Andjelic S, Lacy E et al. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis Activation-induced death can occur without Fas receptor. J. Immunol. 1996; 156: 192-200.
5. 5 Wong B, Arron J, Choi YW. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J. Exp. Med. 1997; 186: 1939-44.
6. 6 Alberolalla J, Takaki S, Kerner JD, Perlmutter RM. Differential signaling by lymphocyte antigen receptors. Annu. Rev. Immunol. 1997; 15: 125-54.
7. 7 Chung CD, Lewis LA, Miceli MC. T cell antigen receptor-induced IL-2 production and apoptosis have different requirements for Lck activities. J. Immunol. 1997; 159: 1758-66.
8. 8 Maier CC, Greene MI. Biochemical features of anergic T cells. Immunol. Res. 1998; 17: 133-40.
9. 9 Walker LSK, McLeod JD, Boulougouris G et al. Down-regulation of CD28 via Fas (CD95): Influence of CD28 on T-cell apoptosis. Immunology 1998; 94: 41-7.
10. 10 Ramsdell F, Seaman MS, Miller RE et al. Differential ability of Th1 And Th2 T-cells to express fas ligand and to undergo activation-induced cell death. Int. Immunol. 1994; 6: 1545-53.
11. 11 Oberg HH, Lengl-Janssen B, Kabelitz D, Janssen O. Activation-induced T cell death: Resistance or susceptibility correlate with cell surface Fas ligand expression and T helper phenotype. Cell. Immunol. 1997; 181: 93-100.
12. 12 Zhang XH, Brunner T, Carter L et al. Unequal death in T helper cell (Th) 1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 1997; 185: 1837-49.
13. 13 Ledru E, Lecoeur H, Garcia S et al. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: Correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J. Immunol. 1998; 160: 3194-206.
14. 14 Desbarats J, Freed JH, Campbell PA, Newell MK. Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4 (+) T cells. Proc. Natl Acad. Sci. USA 1996; 93: 11014-18.
15. 15 Hashimoto F, Oyaizu N, Kalyanaraman VS, Pahwa S. Modulation of Bcl-2 protein by CD4 cross-linking: A possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Blood 1997; 90: 745-53.
16. 16 Howie SEM, Sommerfield AJ, Gray E, Harrison DJ. Peripheral T-lymphocyte depletion by apoptosis after CD4 ligation in vivo: Selective loss of CD44 (-) and 'activating' memory T-cells. Clin. Exp. Immunol. 1994; 95: 195-200.
17. 17 Malcomson RDG, Clarke AR, Peter A et al. Apoptosis induced by gamma-irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo is p53-dependent. J. Pathol. 1997; 181: 166-71.
18. 18 June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol. Today 1994; 15: 321-31.
19. 19 Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit. Rev. Immunol. 1997; 17: 89-118.
20. 20 Durie FH, Foy TM, Masters SR et al. The role of CD40 in the regulation of humoral and cell-mediated-immunity. Immunol. Today 1994; 15: 406-11.
21. 21 Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr. Opin. Immunol 1997; 9: 396-404.
22. 22 Wingren AG, Parra E, Varga M et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. 1995; 15: 235-53.
23. 23 Dubey C, Croft M. Accessory molecule regulation of naive CD4 T cell activation. Immunol. Res. 1996; 15: 114-25.
24. 24 Carter LL, Zhang XH, Dubey C et al. Regulation of T cell subsets from naive to memory. J. Immunotherapy 1998; 21: 181-7.
25. 25 Chatila TA, Schwartz DH, Miller R, Geha RS. Requirement for mitogen, T-cell accessory cell contact, and interleukin-1 in the induction of resting T-cell proliferation. Clin. Immunol. Immunopathol 1987; 44: 235-47.
26. 26 Vink A, Uyttenhove C, Wauters P, Vansnick J. Accessory factors involved in murine T-cell activation distinct roles of interleukin-6, interleukin-1 and tumor-necrosis-factor. Eur. J. Immunol. 1990; 20: 1-6.
27. 27 McKay IA, Leigh IM. Epidermal cytokines and their roles in cutaneous wound-healing. Br. J. Dermatol. 1991; 124: 513-18.
28. 28 Murphy EE, Terres G, Macatonia SE et al. B7 and interleukin-12 cooperate for proliferation and interferon-gamma production by mouse T-helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 1994; 180: 223-31.
29. 29 Egan PJ, Kimpton W, Seow HF et al. Inflammation-induced changes in the phenotype and cytokinc profile of cells migrating through skin and afferent lymph. Immunology 1996; 89: 539-46.
30. 30 Filler SG, Pfunder AS, Spellberg BJ et al. Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect. Immunity 1996; 64: 2609-17.
31. 31 Hilkens C, Snijders A, Vermeulen H et al. Accessory cell-derived interleukin-12 and prostaglandin E-2 determine the level of interferon-gamma produced by activated human CD4 (+) T cells. Ann. N. Y. Acad. Sci. 1996; 795: 349-50.
32. 32 Rochester CL, Ackerman SJ, Zheng T, Elias JA. Eosinophil-fibroblast interactions - Granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J. Immunol. 1996; 156: 4449-56.
33. 33 Rasmussen SJ, Eckmann L, Quayle AJ et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Invest. 1997; 99: 77-87.
34. 34 Joseph SB, Miner KT, Croft M. Augmentation of naive, Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF. Eur. J. Immunol. 1998; 28: 277-89.
35. 35 Jasny BR, Clery D. AIDS Research - 1998. Science 1998; 280: 1855.
36. 36 Hirschberg H. Braathen LR, Thorsby E. Antigen presentation by vascular endothelial-cells and epidermal langerhans cells the role of HLA-DR. Immunol. Rev. 1982; 66: 57-77.
37. 37 Cohen DA, Kaplan AM. Adherent 1a+ murine cell-lines with characteristics of dendritic cells.II. Characteristics of I region-restricted antigen presentation. Cell. Immunol. 1983; 80: 349-62.
38. 38 Ashwell JD, DeFranco AL, Paul WE, Schwartz RH. Antigen presentation by resting B-cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T-cell activation. J. Exp. Med. 1984; 159: 881-905.
39. 39 Krieger JI, Grammer SF, Grey HM, Chesnut RW. Antigen presentation by splenic B-cells - resting B-cells are ineffective, whereas activated B-cells are effective accessory cells for T-cell responses. J. Immunol. 1985; 135: 2937-45.
40. 40 Kapsenberg ML, Teunissen MBM, Stiekema FEM, Keizer HG. Antigen-presenting cell-function of dendritic cells and macrophages in proliferative T-cell responses to soluble and participate antigens. Eur. J. Immunol. 1986; 16: 345-50.
41. 41 Tiegs SL, Evavold BD, Yokoyama A et al. Delayed antigen presentation by epidermal Langerhans cells to cloned Th1 and Th2 cells. J. Invest. Dermatol. 1990; 95: 446-9.
42. 42 Ellis J, Chain BM, Davies DH et al. Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL) 2, IL4 and interferon-gamma by allogeneie T-cells. Eur. J. Immunol. 1991; 21: 2803-9.
43. 43 Croft M. Activation of naive, memory and effector T-cells. Curr. Opin. Immunol. 1994; 6: 431-7.
44. 44 Bulfour BM, Drexhage HA, Kamperdijk EW, Hoefsmit EC. Antigen presenting cells, including Langcrhans cells, veiled cells and interdigitating cells. Ciba Found. Symp. 1981; 84: 281-301.
45. 45 Streilein JW, Grammer SF, Yoshikawa T et al. Functional dichotomy between langerhans cells that present antigen to naive and to memory effector lymphocytes-T. Immunol. Rev. 1990; 117: 159-83.
46. 46 Cumberbatch M, Illingworth I, Kimber I. Antigen-bearing dendritic cells in the draining lymph-nodes of contact sensitized mice cluster formation with lymphocytes. Immunology 1991; 74: 139-45.
47. 47 VanWilsem EJ, Brevé J, Kleijmeer M, Kraal G. Antigen-bearing langerhans cells in skin draining lymph-nodes - phenotype and kinetics of migration. J. Invest. Dermatol. 1994; 103: 217-20.
48. 48 Rattis FM, Péguet-Navarro J, Staquet MJ et al. Expression and function of B7 1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Eur. J. Immunol. 1996; 26: 449-53.
49. 49 Davis CB, Dikic I, Unutmaz D et al. Signal transduction due to HIV 1 envelope interactions with chemokine receptors CXCR4 or CCR5. J. Exp. Med. 1997; 186: 1793-8.
50. 50 Udey MC. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 1997; 107: 6-8.
51. 51 Aiba S, Terunuma A, Manome H, Tagami H. Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur. J. Immunol. 1997; 27: 3031-8.
52. 52 Fox R, Eldred LJ, Fuchs EJ et al. Clinical manifestations of acute infection with human-immunodeficiency-virus in a cohort of gay men. AIDS 1987; 1: 35-8.
53. 53 Buchbinder SP, Katz MH, Hessol NA et al. Long-term HIV-1 infection without immunological progression. AIDS 1994; 8: 1123-8.
54. 54 Levy JA. HIV and the Pathogenesis of AIDS. Washington DC: American Society for Microbiology, 1994.
55. 55 Blanche S. Time-course of pediatric HIV disease and the 1994 classification. Ann. Pediatr. 1996; 43: 7-13.
56. 56 Blanche S, Newell ML, Mayaux MJ et al. Morbidity and mortality in European children vertically infected by HIV-1 - The French pediatric HIV infection study group and European collaborative study. J. AIDS Hum. Retrovirol. 1997; 14: 442-50.
57. 57 Wahl SM, Orenstein JM. Immune stimulation and HIV-1 viral replication. J. Leukoc. Biol. 1997; 62: 67-71.
58. 58 Twigg HL, Soliman DM, Spain BA. Impaired alveolar macrophage accessory cell-function and reduced incidence of lymphocytic alveolitis in HIV-infected patients who smoke. AIDS 1994; 8: 611-18.
59. 59 Bagasra O, Kajdacsy-Balla A, Lischner HW, Pomerantz RJ. Alcohol intake increases human-immunodeficiency-virus type-1 replication in human peripheral-blood mononuclear-cells. J. Infect. Dis. 1993; 167: 789-97.
60. 60 Bagasra O, Pomerantz RJ. Human-immunodeficiency-virus type-1 replication in peripheral-blood mononuclear-cells in the presence of cocaine. J. Infect. Dis. 1993; 168: 1157-64.
61. 61 Roger M. Influence of host genes on HIV-1 disease progression. FASEB J. 1998; 12: 625-32.
62. 62 Saah AJ, Hoover DR, Weng SG et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS 1998; 12: 2107-13.
63. 63 Tomiyama H, Miwa K, Shiga H et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte cpitopcs by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J. Immunol. 1997; 158: 5026-34.
64. 64 Itescu S, Rose S, Dwyer E, Winchester R. Certain HLA-DR5 and HLA-DR6 major histocompatibility complex class-II alleles are associated with a CD8 lymphocytic host response to human-immunodeficiency-virus type-1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc. Natl Acad. Sci. USA 1994; 91: 11472-6.
65. 65 Khoo SH, Pepper L, Snowden N et al. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997; 11: 423-8.
66. 66 Brinkman BN, Keet IPM, Miedema F et al. Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons. J. Infect. Dis. 1997; 175: 188-90.
67. 67 Cameron PU, Mallal SA, French MH, Dawkins RL. Major histocompatibility complex genes influence the outcome of HIV-infection - ancestral haplotypes with c4 null alleles explain diverse HLA associations. Hum. Immunol. 1990; 29: 282-95.
68. 68 Hentges F, Hoffmann A, Dearaujo FO, Hemmer R. Prolonged clinically asymptomatic evolution after HIV-1 infection is marked by the absence of complement-C4 null alleles at the MHC. Clin. Exp. Immunol. 1992; 88: 237-42.
69. 69 Garred P, Madsen HO, Balslev U et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236-40.
70. 70 Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 1997; 159; 31-48.
71. 71 Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279: 389-93.
72. 72 VanRij RP, Broersen S, Goudsmit J et al. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998; 12: F85-90.
73. 73 Huang YX, Zhang LQ, Ho DD. Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 1998; 240: 36-49.
74. 74 Connor RI, Ho DD. Human-immunodeficiency-virus type-1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 1994; 68: 4400-8.
75. 75 Schuitemaker H, Koot M, Kootstra NA et al. Biological phenotype of human-immunodeficiency-virus type-1 clones at different stages of infection - progression of disease is associated with a shift from monocytotropic to t-cell-tropic virus populations. J. Virol. 1992; 66: 1354-60.
76. 76 Kirchhoff F, Greenough TC, Brettler DB et al. Brief report absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 1995; 332: 228-32.
77. 77 Mariani R, Kirchhoff F, Greenough TC et al. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 1996; 70: 7752-64.
78. 78 Michael NL, Chang G, Darcy LA et al. Defective accessory genes in a human-immunodeficiency-virus type-1 infected long-term survivor lacking recoverable virus. J. Virol. 1995; 69: 4228-36.
79. 79 Michael NL, Chang G, Darcy LA et al. Functional characterisation of human-immunodcficicncy-virus type-1 nef genes in patients with divergent rates of disease progression. J. Virol. 1995; 69: 6758-69.
80. 80 Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi-species of HIV-1 from a blood-transfusion donor and recipients. Science 1995; 270: 988-91.
81. 81 Wang B, Ge YC, Palasanthiran P et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: In vivo evolution of vpr quasi-species in blood and plasma. Virology 1996; 223: 224-32.
82. 82 Zhang LQ, Huang YX, Yuan H et al. Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 1997; 71: 5608-13.
83. 83 Premkumar DRD, Ma XZ, Maitra RK et al. The nef gene from a long-term HIV type 1 nonprogressor. AIDS Res. Hum. Retrovir. 1996; 12: 337-45.
84. 84 Menzo S, Sampaolesi R, Vicenzi E et al. Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. AIDS 1998; 12: 985-97.
85. 85 Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse-transcriptase. Science 1988; 242: 1168-71.
86. 86 Simon F, Mauelere P, Roques P et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 1998; 4: 1032-7.
87. 87 Pope M, Ho DD, Moore JP et al. Different subtypes of HIV-1 and cutaneous dendritic cells. Science 1997; 278: 786-7.
88. 88 Soto-Ramirez LE, Renjifo B, McLane MF et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996; 271: 1291-3.
89. 89 Dalgleish AG, Beverley PCL, Clapham PR et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-7.
90. 90 D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors - Confluence of two fields generates optimism in AIDS research. Nat. Med. 1996; 2: 1293-300.
91. 91 Center DM, Berman JS, Kornfeld H et al. The lymphocyte chemoattractant factor. J. Lab. Clin. Invest. 1995; 125: 167-72.
92. 92 Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
93. 93 Baggiolini M, Dewald B, Moser B. Human chemokines: An update. Annu. Rev. Immunol. 1997; 15: 675-705.
94. 94 Verrier FC, Charneau P, Altmeyer R et al. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proc. Natl Acad. Sci. USA 1997; 94: 9326-31.
95. 95 Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 1997; 9: 551-62.
96. 96 Stent G, Joø GB, Kierulf P, Ǎsjö B. Macrophage tropism: Fact or fiction? J. Leukoc. Biol. 1997; 62: 4-11.
97. 97 Martin MP, Dean M, Smith MW et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-11.
98. 98 Mummidi S, Ahuja SS, Gonzalez E et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rales of HIV-1 disease progression. Nat. Med. 1998; 4: 786-93.
99. 99 Quillent C, Oberlin E, Braun J et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351: 14-18.
100. 100 Landau NR. HIV co-receptor identification: Good or bad news for drug discovery? Curr. Opin. Immunol. 1997; 9: 628-30.
101. 101 Michael NL, Chang G, Louie LG et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 1997; 3: 338-40.
102. 102 Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
103. 103 Hoffman TL, MacGregor RR, Burger H et al. CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J. Infect. Dis. 1997; 176: 1093-6.
104. 104 Edelstein RE, Arcuino LAM, Hughes JP et al. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/Delta 32ccr5 heterozygotes. J. AIDS Hum. Retrovirol. 1997; 16: 243-6.
105. 105 Rousseau CM, Just JJ, Abrams EJ et al. CCR5delta32 in perinatal HIV-1 infection. J. AIDS Hum. Retrovirol. 1997; 16: 239-42.
106. 106 McDermott DH, Zimmerman PA, Guignard F et al. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998; 352: 866-70.
107. 107 Garred P. Chemokine-receptor polymorphisms: Clarity or confusion for HIV-1 prognosis? Lancet 1998; 351: 2-3.
108. 108 Horuk R. Chemokine receptors and HIV-1: The fusion of two major research fields. Immunol. Today 1999; 20: 89-94.
109. 109 Laurence J, Hodtsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T-cells on TCR V-beta expression. Nature 1992; 358: 255-9.
110. 110 Karray S, Zouali M. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc. Natl Acad. Sci. USA 1997; 94: 1356-60.
111. 111 Ankel H, Capobianchi MR, Frezza F et al. Interferon induction by HIV-1-infected cells: A possible role of sulfatides or related glycolipids. Virology 1996; 221: 113-19.
112. 112 Gessani S, Borghi P, Fantuzzi L et al. Induction of cytokines by HIV-1 and its gp120 protein in human peripheral blood monocyte/macrophages and modulation of cytokine response during differentiation. J. Leukoc. Biol. 1997; 62: 49-53.
113. 113 Clerici M, Shearer GM. A Th1 -Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-10.
114. 114 Poli G, Fauci AS. Cytokine modulation and HIV expression. Semin. Immunol. 1993; 5: 165-73.
115. 115 Romagnani S, DelPrete G, Manetti R et al. Role of T(h) 1/T(h) 2 cytokines in HIV-infection. Immunol. Rev. 1994, 140: 73-92.
116. 116 Romagnani S, Maggi E, DelPrete G. HIV can induce a T(h) 1 to T(h) 0 shift, and preferentially replicates in CD4 (+) T-cell clones producing T(h) 2-Type cytokines. Res. Immunol. 1994; 145: 611-18.
117. 117 Ito M, Ishida T, He LM et al. HIV type I Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS Res. Hum. Retrovir. 1998; 14: 845-9.
118. 118 Graziosi C, Pantaleo G, Gantt KR et al. Lack of evidence for the dichotomy of T(h) 1 And T(h) 2 predominance in HIV-infected individuals. Science 1994; 265: 248-52.
119. 119 Miedema F, Meyaard L, Kool M et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol. Rev. 1994; 140: 35-72.
120. 120 Maggi E, Mazzetti M, Ravina A et al. Ability of HIV to promote a T(h)1 to T(h)0 shift and to replicate preferentially in T(h)2 and T(h)0 cells. Science 1994; 265: 244-8.
121. 121 Vyakarnam A, Matear PM, Martin SJ, Wagstaff M. Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus-replication in Th0 cells. Immunology 1995; 86: 85-96.
122. 122 Meyaard L, Hovenkamp E, Keet IPM et al. Single-cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals Decreased IFN-gamma in the presence of preserved IL-4 production. J. Immunol. 1996; 157: 2712-8.
123. 123 Klein SA, Dobmeyer JM, Dobmeyer TS et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997; 11: 1111-18.
124. 124 Hubert P, Bismuth G, Korner M, Debre P. HIV-1 glycoprotein gp120 disrupts CD4-p56 (Lck)/CD3-T cell-receptor interactions and inhibits CD3 signaling. Eur. J. Immunol. 1995; 25: 1417-25.
125. 125 Hewson TJ, Howie SEM. The effects of HIV gp120 on the expression of antigen presenting cell (APC) surface molecules. Immunology 1998; 95: 86.
126. 126 Kestler HW, Ringler DJ, Mori K et al. Importance of the nef gene for maintenance of high virus loads and for development of aids. Cell 1991; 65: 651-62.
127. 127 De SK, Venkateshan CS, Seth P et al. Adenovirus-mediated human immunodeficiency virus-1 nef expression in human monocytes/macrophages and effect of nef on downmodulation of Fc gamma receptors and expression of monokines. Blood 1998; 91: 2108-17.
128. 128 Craig HM, Pandori MW, Guatelli JC. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl Acad. Sci. USA 1998; 95: 11229-34.
129. 129 Peter F. HIV nef: The mother of all evil? Immunity 1998; 9: 433-7.
130. 130 Schwartz O, Marechal V, LeGall S et al. Endocytosis of major histocompatibility complex class 1 molecules is induced by the HIV-1 Nef protein. Nat. Med. 1996; 2: 338-42.
131. 131 Rhee SS, Marsh JW. Human-immunodeficiency-virus type-1 nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J. Virol. 1994; 68: 5156-63.
132. 132 Cullen BR. HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 1998; 93: 685-92.
133. 133 Willey RL, Maldarelli F, Martin MA, Strebel K. Human-immunodeficiency-virus type-1 vpu protein induces rapid degradation of CD4. J. Virol. 1992; 66: 7193-200.
134. 134 Bour S, Geleziunas R, Wainberg MA. The human-immunodeficiency-virus type-1 (HIV-1 ), CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol. Rev. 1995; 59: 63-93.
135. 135 Cottrez F, Manca F, Dalgleish AG et al. Priming of human CD4 (+) antigen-specific T cells to undergo apoptosis by HIV-infected monocytes - A two-step mechanism involving the gp120 molecule. J. Clin. Invest. 1997; 99: 257-66.
136. 136 Mosier D, Sieburg H. Macrophage-tropic HIV - critical for AIDS pathogenesis. Immunol. Today 1994; 15: 332-9.
137. 137 Gougeon ML, Montagnier L. Apoptosis in AIDS. Science 1993; 260: 1269-70.
138. 138 Ameisen JC, Estaquier J, Idziorek T. From AIDS to parasite infection - pathogen-mediated subversion of programmed cell-death as a mechanism for immune dysregulation. Immunol. Rev. 1994; 142: 9-51.
139. 139 Ameisen JC, Estaquier J, Idziorek T, Debels F. The relevance of apoptosis to AIDS pathogenesis. Trends Cell Biol. 1995; 5: 27-32.
140. 140 Montagnier L. Nef vaccination against HIV disease. Lancet 1995; 346: 1170.
141. 141 DeSimone C, Famularo G, Cifone G, Mitsuya H. HIV-1 infection and cellular metabolism. Immunol. Today 1996; 17: 256-8.
142. 142 Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol. Today 1994; 15: 7-10.
143. 143 Greenspan HC, Aruoma OI. Oxidative stress and apoptosis in HIV-infection - a role for plant-derived metabolites with synergistic antioxidant activity. Immunol. Today 1994; 15: 209-13.
144. 144 Zauli G, Davis BR, Re MC et al. Tat protein stimulates production of transforming growth factor-beta-1 by marrow macrophages - a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood 1992; 80: 3036-43.
145. 145 Frankel AD, Pabo CO. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
146. 146 Westendorp MO, Liweber M, Frank RW, Krammer PH. Human immunodeficiency virus type-1 Tat up-regulates interleukin-2 secretion in activated T-cells. J. Virol. 1994; 68: 4177-85.
147. 147 Dezube BJ, Pardee AB, Beckett LA et al. Cytokine dysregulation in AIDS in vivo overexpression of messenger-RNA of tumor-necrosis-factor-alpha and its correlation with that of the inflammatory cytokine Gro. J. AIDS Hum. Retrovirol. 1992; 5: 1099-104.
148. 148 Derossi A, Ometto L, Roncella S et al. HIV-1 induces down-regulation of bcl-2 expression and death by apoptosis of EBV-immortalized B-cells - a model for a persistent self-limiting HIV-1 infection. Virology 1994; 198: 234-44.
149. 149 Miller MA, Cloyd MW, Liebmann J et al. Alterations in cell-membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993; 196: 89-100.
150. 150 Werner T, Ferroni S, Saermark T et al. HIV-1 nef protein exhibits structural and functional similarity to scorpion peptides interacting with K+ channels. AIDS 1991; 5: 1301-8.
151. 151 Garry RF, Koch G. Tat contains a sequence related to snake neurotoxins. AIDS 1992; 6: 1541-2.
152. 152 Sabatier JM, Vives E, Mabrouk K et al. Evidence for neurotoxic activity of tat from human-immunodeficiency-virus type-1. J. Virol. 1991; 65: 961-7.
153. 153 Thornton AM, Buller RML, Devico AL et al. Inhibition of human immunodeficiency virus type 1 and vaccinia virus infection by a dominant negative factor of the interferon regulatory factor family expressed in monocytic cells. Proc. Natl Acad. Sci. USA 1996; 93: 383-7.
154. 154 Prohaszka Z, Nemes J, Hidvegi T et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 1997; 11: 949-58.
155. 155 Toth FD, Mosborg-Petersen P, Kiss J et al. Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in-vitro. Clin. Exp. Immunol. 1994; 96: 389-94.
156. 156 Perno CF, Baseler MW, Broder S, Yarchoan R. Infection of monocytes by human-immunodeficiency-virus type-1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J. Exp. Med. 1990; 171: 1043-56.
157. 157 Pereira FB, Goñi FM, Muga A, Nieva JL. Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: Dose and sequence effects. Biophys. J. 1997; 73: 1977-80.
158. 158 Stevenson M, Haggerty S, Lamonica CA et al. Integration is not necessary for expression of human-irnmunodeficiency-virus type-1 protein products. J. Virol. 1990; 64: 2421-5.
159. 159 Sun Y, Pinchuk LM, Agy MB, Clark EA. Nuclear import of HIV-1 DNA in resting CD4(+) T cells requires a cyclosporin A-sensitive pathway. J. Immunol. 1997; 158: 512-17.
160. 160 Zack JA, Arrigo SJ, Weitsman SR et al. HIV-1 entry into quiescent primary lymphocytes - molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-22.
161. 161 Zack JA, Haislip AM, Krogstad P, Chen IY. Incompletely reverse-transcribed human-immunodeficiency-virus type-1 genomes in quiescent cells can function as intermediates in the retroviral life-cycle. J. Virol. 1992; 66: 1717-25.
162. 162 Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998; 93: 665-71.
163. 163 Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human-immunodeficiency-virus type-1 (HIV-1) infection of non-proliferating human monocytes. J. Exp. Med. 1991; 174: 1477-82.
164. 164 Crowe SM, Lopez A. GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage. J. Leukoc. Biol. 1997; 62: 41-8.
165. 165 Kruger M, VanDeWinkel JGJ, Dewit TPM et al. Granulocyte-macrophage colony-stimulating factor down-regulates CD14 expression on monocytes. Immunology 1996; 89: 89-95.
166. 166 Bagasra O, Wright SD, Seshamma T et al. CD14 is involved in control of human-immunodeficiency-virus type-1 expression in latently infected-cells by lipopolysaccharide. Proc. Natl Acad. Sci. USA 1992; 89: 6285-9.
167. 167 Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene-expression. AIDS 1992; 6: 347-63.
168. 168 Alcami J, Delera TL, Folgueira L et al. Absolute dependence on kappa-B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4T-lymphocytes. EMBO J. 1995; 14: 1552-60.
169. 169 Wright SD, Ramos RA, Tobias PS et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding-protein. Science 1990; 249: 1431-3.
170. 170 Kedzierska K, Rainbird MA, Lopez AF, Crowe SM. Effect of GM-CSF on HIV-1 replication in monocytes/macrophages in vivo and in vitro: A review. Vet. Immunol. Immunopathol. 1998; 63: 111-21.
171. 171 Burke D. Recombination in HIV: An important evolutionary strategy. Emerg. Infect. Dis. 1997; 3: 1-9.
172. 172 Granelli-Piperno A, Pope M, Inaba K, Steinman RM. Coexpression of NF-kappa-B/Rel and Spl transcription factors in human-immunodeficieney-virus 1-induced, dendritic cell T-cell syneytia. Proc. Natl Acad. Sci. USA 1995; 92: 10944-8.
173. 173 Knight SC, Patterson S. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu. Rev. Immunol. 1997; 15: 593-615.
174. 174 Schattner A, Ragerzisman B. Virus-induced autoimmunity. Rev. Infect. Dis. 1990; 12: 204-22.
175. 175 Gabrilovich DI, Woods GM, Patterson S et al. Retrovirus-induced immunosuppression via blocking of dendritic cell-migration and down-regulation of adhesion molecules. Immunology 1994; 82: 82-7.
176. 176 Kuchroo VK, Das MP, Brown JA et al. B7 1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways - application to autoimmune-disease therapy. Cell 1995; 80: 707-18.
177. 177 Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994; 12: 991-1045.
178. 178 Bukrinsky MI, Nottet HSLM, Schmidtmayerova H et al. Regulation of nitric-oxide synthase activity in human-immunodeficiency-virus type-1 (HIV-1)-infected monocytes - implications for HIV-associated neurological disease. J. Exp. Med. 1995; 181: 735-45.
179. 179 Miller CJ, Alexander NJ, Sutjipto S et al. Genital mucosal transmission of simian immunodeficiency virus - animal-model for heterosexual transmission of human immunodeficiency virus. J. Virol. 1989; 63: 4277-84.
180. 180 Spira AI, Marx PA, Patterson BK et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 1996; 183: 215-25.
181. 181 Weissman D, Li Y, Orenstein JM, Fauci AS. Both a precursor and a mature population of dendritic cells can hind HIV -however, only the mature population that expresses CD80 can pass infection to unstimulated CD4 (+) T-cells. J. Immunol. 1995; 155: 4111-17.
182. 182 Clumeck N, Hermans P. The complications of survival: Haematological and oncological features of AIDS. Helix 1996; 5: 20-7.